ACTengine
Phase 1/2 Recruiting
375 enrolled
NBM-BMX-UM
Phase 1/2 Recruiting
36 enrolled
PIVOT IO 020
Phase 1/2 Terminated
15 enrolled 14 charts
REVEAL
Phase 1/2 Terminated
64 enrolled 22 charts
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Phase 1/2 Completed
58 enrolled 18 charts
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
Phase 1/2 Completed
21 enrolled
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Phase 1/2 Completed
37 enrolled
MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma
Phase 1/2 Completed
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
Phase 1/2 Withdrawn
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
Phase 1/2 Completed
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
Phase 1/2 Completed